Compare LEVI & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LEVI | PODD |
|---|---|---|
| Founded | 1853 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6B | 10.3B |
| IPO Year | 2019 | 2007 |
| Metric | LEVI | PODD |
|---|---|---|
| Price | $21.34 | $143.81 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 21 |
| Target Price | $26.92 | ★ $341.48 |
| AVG Volume (30 Days) | ★ 1.7M | 1.7M |
| Earning Date | 04-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.56% | N/A |
| EPS Growth | ★ 178.85 | N/A |
| EPS | 0.67 | ★ 2.67 |
| Revenue | ★ $6,282,000,000.00 | $2,708,100,000.00 |
| Revenue This Year | $8.64 | $24.55 |
| Revenue Next Year | $4.82 | $19.18 |
| P/E Ratio | ★ $31.48 | $53.58 |
| Revenue Growth | N/A | ★ 30.73 |
| 52 Week Low | $17.72 | $126.40 |
| 52 Week High | $25.70 | $354.88 |
| Indicator | LEVI | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 29.02 | 41.23 |
| Support Level | $20.41 | $139.23 |
| Resistance Level | $22.45 | $170.20 |
| Average True Range (ATR) | 0.59 | 5.25 |
| MACD | -0.21 | -0.15 |
| Stochastic Oscillator | 7.08 | 28.65 |
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver; Europe; and Asia.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.